Compare Stocks: EGRX, VYNE, TVRD, and LPCN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$0.05 -0.4%	$0.55	$0.00 ▼ $3.73	$660K	0.83	8,833 shs	397 shs
LPCN Lipocine	$2.13 -1.8%	$2.27	$1.81 ▼ $12.37	$17.89M	0.46	39,316 shs	31,811 shs
TVRD Tvardi Therapeutics	$1.85 -7.5%	$2.65	$1.50 ▼ $43.65	$18.76M	0.39	1.28 million shs	519,522 shs
VYNE VYNE Therapeutics	$28.33 -0.8%	$33.15	$14.03 ▼ $79.75	$18.98M	2	44,151 shs	93,278 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	-86.22%	-86.22%	-92.39%	-86.58%	-98.40%
LPCN Lipocine	+1.88%	+4.83%	-12.15%	-9.21%	-29.55%
TVRD Tvardi Therapeutics	-1.48%	-6.54%	-0.50%	-52.49%	-92.30%
VYNE VYNE Therapeutics	0.00%	0.00%	-15.14%	-15.89%	+57.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$0.05 -0.4%	$0.55	$0.00 ▼ $3.73	$660K	0.83	8,833 shs	397 shs
LPCN Lipocine	$2.13 -1.8%	$2.27	$1.81 ▼ $12.37	$17.89M	0.46	39,316 shs	31,811 shs
TVRD Tvardi Therapeutics	$1.85 -7.5%	$2.65	$1.50 ▼ $43.65	$18.76M	0.39	1.28 million shs	519,522 shs
VYNE VYNE Therapeutics	$28.33 -0.8%	$33.15	$14.03 ▼ $79.75	$18.98M	2	44,151 shs	93,278 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	-86.22%	-86.22%	-92.39%	-86.58%	-98.40%
LPCN Lipocine	+1.88%	+4.83%	-12.15%	-9.21%	-29.55%
TVRD Tvardi Therapeutics	-1.48%	-6.54%	-0.50%	-52.49%	-92.30%
VYNE VYNE Therapeutics	0.00%	0.00%	-15.14%	-15.89%	+57.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
LPCN Lipocine	2.33	Hold	$15.00	604.23% Upside
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	872.97% Upside
VYNE VYNE Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest EGRX, VYNE, TVRD, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
6/18/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	TVRD Tvardi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EGRX Eagle Pharmaceuticals	$257.55M	0.00	$0.13 per share	0.40	N/A	∞
LPCN Lipocine	$1.98M	8.86	N/A	N/A	$2.64 per share	0.81
TVRD Tvardi Therapeutics	$7.14M	2.43	N/A	N/A	$2.23 per share	0.83
VYNE VYNE Therapeutics	$570K	33.29	N/A	N/A	$41.71 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.04	N/A	N/A	N/A	N/A	N/A	8/11/2026 (Estimated)
LPCN Lipocine	-$9.63M	-$1.88	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	N/A
TVRD Tvardi Therapeutics	-$18.21M	-$3.10	N/A	N/A	N/A	N/A	-64.17%	-43.90%	N/A
VYNE VYNE Therapeutics	-$26.48M	-$0.38	N/A	N/A	N/A	-4,726.21%	-70.42%	-63.46%	8/13/2026 (Estimated)

Latest EGRX, VYNE, TVRD, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	VYNE VYNE Therapeutics	-$0.18	N/A	N/A	N/A	$0.20 million	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million
5/15/2026	Q1 2026	VYNE VYNE Therapeutics	-$9.00	-$4.00	+$5.00	-$0.08	$0.20 million	$0.09 million
5/8/2026	Q1 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.73	-$0.08	-$0.73	N/A	N/A
5/7/2026	Q1 2026	LPCN Lipocine	-$0.51	-$0.54	-$0.03	-$0.54	$0.16 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest EGRX, VYNE, TVRD, and LPCN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	VYNE VYNE Therapeutics	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
LPCN Lipocine	N/A	11.48	9.99
TVRD Tvardi Therapeutics	N/A	2.25	2.25
VYNE VYNE Therapeutics	N/A	20.86	20.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EGRX Eagle Pharmaceuticals	85.36%
LPCN Lipocine	9.11%
TVRD Tvardi Therapeutics	44.66%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
EGRX Eagle Pharmaceuticals	28.90%
LPCN Lipocine	4.69%
TVRD Tvardi Therapeutics	7.40%
VYNE VYNE Therapeutics	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
LPCN Lipocine	10	8.24 million	7.86 million	No Data
TVRD Tvardi Therapeutics	80	9.38 million	8.69 million	N/A
VYNE VYNE Therapeutics	30	670,000	648,000	Not Optionable

EGRX, VYNE, TVRD, and LPCN Headlines

Recent News About These Companies

VYNE Therapeutics (VYNE) Projected to Post Earnings on Thursday

August 6 at 2:26 AM | americanbankingnews.com

Guardian Pharmacy Services (NYSE:GRDN) versus VYNE Therapeutics (NASDAQ:VYNE) Critical Contrast

August 3 at 3:58 AM | americanbankingnews.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

VYNE Therapeutics (NASDAQ:VYNE) Sees Large Volume Increase - Here's Why

July 27, 2026 | marketbeat.com

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...

July 27, 2026 | finance.yahoo.com

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

July 23, 2026 | globenewswire.com

VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with ...

July 22, 2026 | finanznachrichten.de

VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update

July 22, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 21, 2026 | globenewswire.com

Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend?

July 10, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience

July 10, 2026 | quiverquant.comQ

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 10, 2026 | globenewswire.com

VYNE Therapeutics Insider Trading Activity | NASDAQ:VYNE | Benzinga

July 1, 2026 | benzinga.com

VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04

May 15, 2026 | msn.com

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

December 18, 2025 | prnewswire.com

3 penny stocks to watch now, 12/18/25

December 18, 2025 | msn.com

VYNE to merge with Yarrow in $200 million deal

December 18, 2025 | thepharmaletter.comT

Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience

December 17, 2025 | pharmexec.comP

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

December 17, 2025 | prnewswire.com

VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders

December 17, 2025 | businesswire.com

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

December 17, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, VYNE, TVRD, and LPCN Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

$0.05 0.00 (-0.39%)

As of 01:21 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Lipocine NASDAQ:LPCN

$2.13 -0.04 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 -0.01 (-0.70%)

As of 04:10 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Tvardi Therapeutics NASDAQ:TVRD

$1.85 -0.15 (-7.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 -0.01 (-0.76%)

As of 06:24 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

VYNE Therapeutics NASDAQ:VYNE

$28.32 -0.24 (-0.82%)

Closing price 07/27/2026

Extended Trading

$28.32 0.00 (0.00%)

As of 07/27/2026 07:48 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, VYNE, TVRD, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, VYNE, TVRD, and LPCN Earnings

Compare Dividends

Latest EGRX, VYNE, TVRD, and LPCN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, VYNE, TVRD, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, VYNE, TVRD, and LPCN Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

Lipocine NASDAQ:LPCN

Tvardi Therapeutics NASDAQ:TVRD

VYNE Therapeutics NASDAQ:VYNE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, VYNE, TVRD, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, VYNE, TVRD, and LPCN Earnings

Compare Dividends

Latest EGRX, VYNE, TVRD, and LPCN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, VYNE, TVRD, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, VYNE, TVRD, and LPCN Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

Lipocine NASDAQ:LPCN

Tvardi Therapeutics NASDAQ:TVRD

VYNE Therapeutics NASDAQ:VYNE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools